Energenesis Tackles Diabetic Ulcers with Energy-Restoring Gel

TAIPEI, Taiwan – April 29, 2026 – A novel therapeutic approach that aims to "recharge" the body's own healing mechanisms is offering new hope for one of diabetes's most devastating complications. Taipei-based Energenesis Biomedical is set to present clinical insights on its investigational drug, ENERGI-F703DFU, a topical gel for chronic diabetic foot ulcers (DFUs), at the prestigious European Wound Management Association (EWMA) 2026 conference in Bremen, Germany.

The announcement spotlights a potential breakthrough in a field grappling with limited effective treatments. For millions worldwide, DFUs are a persistent threat, often leading to severe infections, prolonged hospital stays, and lower-limb amputations. Energenesis's candidate takes a unique path, targeting the underlying cellular energy deficit that stalls the healing process in chronic wounds. The company will share case-based clinical experiences at the EWMA's New Tech Industry Symposium on May 6, providing a glimpse into the therapy's real-world potential ahead of pivotal trial results.

A Crippling Unmet Need

Diabetic foot ulcers are far more than just a surface wound. They are a stark manifestation of the systemic damage caused by diabetes, arising from a combination of nerve damage (neuropathy) and poor circulation. This perilous combination means patients may not feel an initial injury, and once a wound develops, the body's impaired ability to heal can turn a minor sore into a non-healing, deep ulcer.

The global healthcare burden is staggering. The DFU treatment market, valued at over $5 billion in 2023, is projected to climb towards $8 billion by 2030, driven by the rising tide of diabetes prevalence. However, this market value also reflects the high cost and often limited success of current treatments. The gold standard of care involves a multi-pronged approach: meticulous debridement (removing dead tissue), infection management, and "off-loading" pressure from the affected foot.

While essential, these measures are often not enough. Advanced treatments, including specialized dressings, negative pressure wound therapy, and bioengineered skin substitutes, have improved outcomes for some, but a significant portion of patients still struggle with wounds that refuse to close. This treatment gap has devastating consequences, with DFU being the leading cause of non-traumatic lower-limb amputations globally.

"The current standard of care is primarily about managing the wound environment," noted one independent wound care specialist. "We can clean it, we can cover it, we can take pressure off it. But we have very few tools that actively stimulate the patient's own cells to heal faster. That's the holy grail."

Recharging the Healing Process

Energenesis Biomedical believes it is closing in on that grail by tackling the problem at a fundamental biological level: cellular energy. Chronic wounds are often stuck in a state of inflammation and metabolic shutdown. The cells responsible for rebuilding tissue—epithelial cells—lack the energy, in the form of adenosine triphosphate (ATP), to proliferate and close the wound.

ENERGI-F703DFU is a potentially first-in-class small-molecule gel designed to directly address this energy crisis. Applied topically, it is engineered to permeate the wound site and boost intracellular ATP levels. By essentially recharging the cellular batteries, the therapy aims to reactivate the body's intrinsic repair mechanisms, promoting cell regeneration and accelerating wound closure.

This innovative mechanism is not just theoretical. A post-hoc analysis of the company's Phase II trial provided compelling evidence. Among a specific subgroup of patients with Wagner Grade 1 to 2 ulcers—the same group now being studied in the Phase III trial—the results were striking. Over a 12-week period, 36.7% of patients treated with ENERGI-F703DFU achieved complete wound closure, compared to just 9.1% in the placebo (vehicle) group. This statistically significant difference provided the strong signal needed to advance the drug into a large-scale, confirmatory Phase III study.

Navigating the Path to Market

That pivotal Phase III trial (NCT05930210) is currently enrolling patients across multiple centers in Taiwan and the United States. The randomized, double-blind study will treat patients for 16 weeks, rigorously evaluating the gel's efficacy and safety against a vehicle control. A positive outcome from this trial would pave the way for regulatory submissions and could position ENERGI-F703DFU as a cornerstone of DFU therapy.

The company is entering a competitive but ripe-for-disruption market. While dominated by wound dressing and device giants like Solventum and Smith+Nephew, the pharmaceutical intervention space has fewer players. ENERGI-F703DFU's classification as a small-molecule drug delivered in a simple topical gel could give it a significant advantage in terms of ease of use and integration into existing treatment protocols.

The upcoming presentation at EWMA, one of the world's largest gatherings of wound care experts, is a strategic move to build awareness and prime the medical community for this new therapeutic class. Sharing clinical case studies can translate trial data into a tangible narrative that resonates with practitioners on the front lines of patient care.

Energenesis's focus on cellular energy restoration extends beyond diabetic wounds. The company's pipeline showcases a platform technology with broad potential, including candidates for alopecia (hair loss), the rare skin blistering disorder epidermolysis bullosa (EB), and the neurodegenerative disorder Parkinson's disease. This diverse portfolio suggests a deep-seated belief in their core scientific approach. While still a clinical-stage company operating at a loss—typical for the biotech industry—Energenesis holds a strong cash position, providing the necessary runway to see its lead candidate through the final stages of clinical development. For the millions at risk of diabetic foot ulcers, the energy this small company is bringing to the field could make all the difference.